论文部分内容阅读
目的 :探讨人工肝支持系统 (ALSS)治疗重型病毒性肝炎的临床疗效。方法 :设治疗组和对照组。治疗组 17例重型病毒性肝炎患者在综合护肝基础上给予ALSS治疗 5 5次。对照组 2 1例仅给予综合护肝治疗。结果 :17例患者经ALSS治疗后 ,症状减轻 ,血清总胆红素从平均 45 9 2 8μmol/L降至 2 46 18μmol/L( P <0 .0 5 ) ,凝血酶原时间从 2 9 13秒缩短至 2 0 5 9秒 ( P <0 0 5 ) ,总存活率为 5 8 5 % ,明显高于对照组 19% ,( P <0 0 1)。早中期生存率 75 %明显高于晚期 2 0 % (P <0 0 5 )。ALSS治疗的并发症主要有皮疹、寒战、低血压等 ,大多数患者能耐受。结论 :ALSS是治疗重型病毒性肝炎的安全、有效的方法 ,早中期效果好。
Objective: To investigate the clinical efficacy of artificial liver support system (ALSS) in the treatment of severe viral hepatitis. Methods: The treatment group and control group. Seventeen patients with severe viral hepatitis in the treatment group were treated with ALSS on the basis of comprehensive liver protection for 55 times. Control group, 21 cases were given comprehensive liver protection. Results: After treatment with ALSS in 17 patients, the symptoms were relieved. The serum total bilirubin was decreased from 45 9 2 8 μmol / L to 466 μmol / L (P <0.05), and the prothrombin time was from 2 9 13 (P0.05). The overall survival rate was 58.5%, significantly higher than that of the control group (19%, P <0.01). The early-mid-term survival rate was 75% significantly higher than the late 20% (P <0 05). ALSS treatment of complications mainly rash, chills, hypotension, most patients can tolerate. Conclusion: ALSS is a safe and effective method for the treatment of severe viral hepatitis with good early and mid-term effects.